Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 79 of 184 for:    carfilzomib OR pr-171

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03158688
Recruitment Status : Active, not recruiting
First Posted : May 18, 2017
Last Update Posted : August 26, 2019
Sponsor:
Information provided by (Responsible Party):
Amgen

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 14, 2019
Estimated Study Completion Date : July 21, 2022